KZIA
KAZIA THERAPEUTICS LTDCurrent holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $0.00 | — | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at KAZIA THERAPEUTICS LTD. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Nov 6, 2013 — the most recent Form 4 on file — not from today.
- Form 40001140361-13-040871Nov 6, 2013
- Form 40001140361-13-039799Oct 29, 2013
- Form 40001140361-13-038912Oct 17, 2013
- Form 40000894579-13-000075Feb 27, 2013
- Form 40001181431-12-062629Dec 5, 2012
- Form 40001181431-12-059896Nov 21, 2012
- Form 40001181431-12-029925May 15, 2012
- Form 40001181431-11-062189Dec 30, 2011
- Form 40001209191-11-050652Oct 5, 2011
- Form 40001209191-11-027170May 10, 2011
- Form 40000945621-08-000063Jul 31, 2008
- Form 40001209191-08-044416Jul 30, 2008
- Form 40000943663-08-000233Mar 27, 2008
- Form 40000943663-07-000521Sep 11, 2007
- Form 40000943663-07-000381Jul 12, 2007
Fundamentals
XBRL · KAZIA THERAPEUTICS LTDNot enough XBRL history to plot. KAZIA THERAPEUTICS LTDhasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for KAZIA THERAPEUTICS LTD — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KREPORT OF FOREIGN PRIVATE ISSUERJun 2, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMay 26, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERApr 27, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERApr 15, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERApr 13, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMar 31, 2026
- 6-KREPORT OF FOREIGN PRIVATE ISSUERMar 30, 2026
- 6-KInterim disclosure (foreign)Mar 19, 2026
- 6-KInterim disclosure (foreign)Jan 27, 2026
- 6-KInterim disclosure (foreign)Dec 19, 2025
- 6-KInterim disclosure (foreign)Dec 10, 2025
- 6-KInterim disclosure (foreign)Dec 5, 2025
- 6-KInterim disclosure (foreign)Dec 2, 2025
- 6-KInterim disclosure (foreign)Nov 18, 2025
- 20-FAnnual report (foreign)Nov 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.